跳至主要内容
临床试验/NCT00193388
NCT00193388已完成2 期

Phase II Trial of Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer

SCRI Development Innovations, LLC0 个研究点目标入组 100 人开始时间: 2002年9月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
100
主要终点
Overall response rate

研究概览

简要总结

In this phase II trial, we will evaluate the weekly schedule of topotecan in the second-line treatment of patients with small cell lung cancer

详细描述

Upon determination of eligibility, all patients will be receive:

  • Topotecan

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • To be included in this study, you must meet the following criteria:
  • Small Cell Lung cancer
  • Progression after one previous regimen
  • Measurable or evaluable disease
  • Able to perform activities of daily living with assistance
  • Adequate bone marrow, liver and kidney function
  • No more than three previous courses of radiation therapy
  • Accessible for treatment and follow up
  • Must give written informed consent prior to study entry

排除标准

  • You cannot participate in this study if any of the following apply to you:
  • Central nervous system involvement
  • Serious or active infection
  • Serious underlying medical condition
  • Other active neoplasms
  • Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

结局指标

主要结局

Overall response rate

次要结局

  • Median survival
  • 1-year survival
  • Symptomatic improvement

研究者

申办方类型
Other

相似试验

Weekly Topotecan in the Second-Line Treatment of... | 临床试验